FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: First tolerability and feasibility results

Background Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodulatory drug that may inhibit autophagy...

Full description

Saved in:
Bibliographic Details
Published in:Strahlentherapie und Onkologie 2014-10, Vol.190 (10), p.957-961
Main Authors: Bilger, Angelika, Bittner, Martin-Immanuel, Grosu, Anca-L., Wiedenmann, Nicole, Meyer, Philipp T., Firat, Elke, Niedermann, Gabriele, Weber, Wolfgang A., Milanović, Dušan
Format: Article
Language:English
Subjects:
Adult
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - radiotherapy
Case Study
Chloroquine - adverse effects
Chloroquine - therapeutic use
Feasibility Studies
Female
Glioblastoma - diagnostic imaging
Glioblastoma - radiotherapy
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - diagnostic imaging
Neoplasm Recurrence, Local - prevention & control
Oncology
Pilot Projects
Positron-Emission Tomography - methods
Radiation-Sensitizing Agents
Radiopharmaceuticals
Radiotherapy
Radiotherapy Dosage
Radiotherapy, Image-Guided - methods
Treatment Outcome
Tyrosine - analogs & derivatives
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodulatory drug that may inhibit autophagy and increase the radiosensitivity of GBM. Patients and methods Between January 2012 and August 2013, we treated five patients with histologically confirmed rGBM with re-RT and 250 mg CQ daily. Results Treatment was very well tolerated; no CQ-related toxicity was observed. At the first follow-up 2 months after finishing re-RT, two patients achieved partial response (PR), one patient stable disease (SD), and one patient progressive disease (PD). One patient with reirradiated surgical cavity did not show any sign of PD. Conclusion In this case series, we observed encouraging responses to CQ and re-RT. We plan to conduct a CQ dose escalation study combined with re-RT.
ISSN:0179-7158
1439-099X
DOI:10.1007/s00066-014-0693-2